Department of Thoracic Surgery, Suining Central Hospital, An Affiliated Hospital of Chongqing Medical University, Suining 629099, China.
Institute of Surgery, Graduate School, Zunyi Medical University, Zunyi 563002, China.
Cells. 2022 Jan 19;11(3):320. doi: 10.3390/cells11030320.
Non-small cell lung cancer is one of the most common types of malignances worldwide and the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical resection, chemotherapy, radiotherapy, and targeted therapy, with poor therapeutic effectiveness. In recent years, immune checkpoint inhibitors have applied in NSCLC treatment. A large number of experimental studies have shown that immune checkpoint inhibitors are safer and more effective than traditional therapeutic modalities and have allowed for the development of better guidance in the clinical treatment of advanced NSCLC patients. In this review, we describe clinical trials using ICI immunotherapies for NSCLC treatment, the available data on clinical efficacy, and the emerging evidence regarding biomarkers.
非小细胞肺癌是全球最常见的恶性肿瘤之一，也是癌症相关死亡的主要原因。目前，非小细胞肺癌的治疗方法基于手术切除、化疗、放疗和靶向治疗，但疗效不佳。近年来，免疫检查点抑制剂已应用于非小细胞肺癌的治疗。大量的实验研究表明，免疫检查点抑制剂比传统的治疗方式更安全、更有效，并为晚期非小细胞肺癌患者的临床治疗提供了更好的指导。在这篇综述中，我们描述了ICI 免疫疗法在非小细胞肺癌治疗中的临床试验、现有的临床疗效数据以及关于生物标志物的新证据。
